WEBULL
News
BMRN
51.80
+0.06%
0.03
BioMarin Names New Chief Accounting Officer
TipRanks · 17h ago
BioMarin Announces New Compensation Package for Incoming Chief Accounting Officer
Reuters · 18h ago
1 Oversold Stock Primed to Rebound and 2 That Underwhelm
Barchart · 2d ago
Do Options Traders Know Something About BMRN Stock We Don't?
NASDAQ · 2d ago
Weekly Report: what happened at BMRN last week (1208-1212)?
Weekly Report · 3d ago
Stifel Nicolaus Keeps Their Hold Rating on BioMarin Pharmaceutical (BMRN)
TipRanks · 3d ago
Should BioMarin’s Cost Cuts, Roctavian Exit, and Pipeline Shifts Require Action From BMRN Investors?
Simply Wall St · 4d ago
BioMarin (BMRN): Has the Market Overreacted to This Year’s Pullback in a Profitable Rare-Disease Leader?
Simply Wall St · 6d ago
Does The Market Misprice BioMarin After 2025 DCF And Earnings Multiple Signals?
Simply Wall St · 12/10 03:25
Regeneron Pharmaceuticals: Is Wall Street Finally Paying Attention?
Seeking Alpha · 12/08 19:46
August 2026 Options Now Available For BioMarin Pharmaceutical (BMRN)
NASDAQ · 12/08 15:40
Weekly Report: what happened at BMRN last week (1201-1205)?
Weekly Report · 12/08 10:40
How Restructuring-Driven Margin Gains And Higher Guidance At BioMarin (BMRN) Have Changed Its Investment Story
Simply Wall St · 12/06 12:27
BioMarin (BMRN) Valuation Update After Six Straight Earnings Beats and Post-Restructuring Growth Momentum
Simply Wall St · 12/05 05:16
Why Is Xenon Pharmaceuticals (XENE) Up 9.7% Since Last Earnings Report?
NASDAQ · 12/03 16:30
Uber To Rally Around 43%? Here Are 10 Top Analyst Forecasts For Wednesday
Benzinga · 12/03 14:30
This Wayfair Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Benzinga · 12/03 14:10
BioMarin Pharmaceutical Price Target Cut to $60.00/Share From $82.00 by Leerink Partners
Dow Jones · 12/03 13:45
BioMarin Pharmaceutical Cut to Market Perform From Outperform by Leerink Partners
Dow Jones · 12/03 13:45
Leerink Partners Downgrades BioMarin Pharmaceutical to Market Perform, Lowers Price Target to $60
Benzinga · 12/03 13:35
More
Webull provides a variety of real-time BMRN stock news. You can receive the latest news about Biomarin Pharmaceutical Inc through multiple platforms. This information may help you make smarter investment decisions.
About BMRN
BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.